<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref-48">
 <label>48</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Van Der Meeren</surname>
    <given-names>O</given-names>
   </name>
   <name>
    <surname>Hatherill</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Nduba</surname>
    <given-names>V</given-names>
   </name>
   <etal/>
  </person-group>: 
  <article-title>Phase 2b Controlled Trial of M72/AS01 
   <sub>E</sub> Vaccine to Prevent Tuberculosis.
  </article-title>
  <source>
   <italic>N Engl J Med.</italic>
  </source>
  <year>2018</year>;
  <volume>379</volume>(
  <issue>17</issue>):
  <fpage>1621</fpage>â€“
  <lpage>1634</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1803484</pub-id>
  <!--<pub-id pub-id-type="pmcid">6151253</pub-id>-->
  <?supplied-pmid 30280651?>
  <pub-id pub-id-type="pmid">30280651</pub-id>
 </mixed-citation>
</ref>
